Glaucoma

Glaucoma, affecting about 4% of the population over 40 years of age, is an asymptomatic, progressive and irreversible disease which leads to blindness unless adequate treatment is provided early on. Static measurements currently performed by ophthalmologists during office hours do not permit widespread and cost-effective monitoring of dynamic intraocular pressure changes responsible for optic nerve damage.

SENSIMED Triggerfish^® - Continuous IOP Monitoring

The need for continuous monitoring of glaucoma patients has been recognized since several years. Diurnal fluctuations in IOP represent an independent risk factor for glaucoma disease progression despite normal office IOP. A significant percentage of glaucoma patients have intraocular peaks or target pressure breathroughs at night or early morning.

SENSIMED, with its revolutionary SENSIMED Triggerfish^® tool for continuous monitoring of fluctuations in intraocular pressure, will not only revolutionize the way glaucoma is diagnosed and treatment is performed, but will also make a contribution to a deeper understanding of its progression. For the first time it will allow ophtalmologists to personalized the patient's treatment and to monitor the efficacy of the treatment.

Not yet approved for sale in the U.S.A.